Dysregulation of Leukocyte Trafficking in Type 2 Diabetes: Mechanisms and Potential Therapeutic Avenues

Research output: Contribution to journalReview articlepeer-review

Standard

Dysregulation of Leukocyte Trafficking in Type 2 Diabetes : Mechanisms and Potential Therapeutic Avenues. / Pezhman, Laleh; Tahrani, Abd; Chimen, Myriam.

In: Frontiers in cell and developmental biology, Vol. 9, 624184, 22.02.2021.

Research output: Contribution to journalReview articlepeer-review

Harvard

APA

Vancouver

Author

Bibtex

@article{1a2a8b7ccc1b4cd3883e428764e156ba,
title = "Dysregulation of Leukocyte Trafficking in Type 2 Diabetes: Mechanisms and Potential Therapeutic Avenues",
abstract = "Type 2 Diabetes Mellitus (T2DM) is a chronic inflammatory disorder that is characterized by chronic hyperglycemia and impaired insulin signaling which in addition to be caused by common metabolic dysregulations, have also been associated to changes in various immune cell number, function and activation phenotype. Obesity plays a central role in the development of T2DM. The inflammation originating from obese adipose tissue develops systemically and contributes to insulin resistance, beta cell dysfunction and hyperglycemia. Hyperglycemia can also contribute to chronic, low-grade inflammation resulting in compromised immune function. In this review, we explore how the trafficking of innate and adaptive immune cells under inflammatory condition is dysregulated in T2DM. We particularly highlight the obesity-related accumulation of leukocytes in the adipose tissue leading to insulin resistance and beta-cell dysfunction and resulting in hyperglycemia and consequent changes of adhesion and migratory behavior of leukocytes in different vascular beds. Thus, here we discuss how potential therapeutic targeting of leukocyte trafficking could be an efficient way to control inflammation as well as diabetes and its vascular complications.",
author = "Laleh Pezhman and Abd Tahrani and Myriam Chimen",
note = "Copyright {\textcopyright} 2021 Pezhman, Tahrani and Chimen.",
year = "2021",
month = feb,
day = "22",
doi = "10.3389/fcell.2021.624184",
language = "English",
volume = "9",
journal = "Frontiers in cell and developmental biology",
issn = "2296-634X",
publisher = "Frontiers Research Foundation",

}

RIS

TY - JOUR

T1 - Dysregulation of Leukocyte Trafficking in Type 2 Diabetes

T2 - Mechanisms and Potential Therapeutic Avenues

AU - Pezhman, Laleh

AU - Tahrani, Abd

AU - Chimen, Myriam

N1 - Copyright © 2021 Pezhman, Tahrani and Chimen.

PY - 2021/2/22

Y1 - 2021/2/22

N2 - Type 2 Diabetes Mellitus (T2DM) is a chronic inflammatory disorder that is characterized by chronic hyperglycemia and impaired insulin signaling which in addition to be caused by common metabolic dysregulations, have also been associated to changes in various immune cell number, function and activation phenotype. Obesity plays a central role in the development of T2DM. The inflammation originating from obese adipose tissue develops systemically and contributes to insulin resistance, beta cell dysfunction and hyperglycemia. Hyperglycemia can also contribute to chronic, low-grade inflammation resulting in compromised immune function. In this review, we explore how the trafficking of innate and adaptive immune cells under inflammatory condition is dysregulated in T2DM. We particularly highlight the obesity-related accumulation of leukocytes in the adipose tissue leading to insulin resistance and beta-cell dysfunction and resulting in hyperglycemia and consequent changes of adhesion and migratory behavior of leukocytes in different vascular beds. Thus, here we discuss how potential therapeutic targeting of leukocyte trafficking could be an efficient way to control inflammation as well as diabetes and its vascular complications.

AB - Type 2 Diabetes Mellitus (T2DM) is a chronic inflammatory disorder that is characterized by chronic hyperglycemia and impaired insulin signaling which in addition to be caused by common metabolic dysregulations, have also been associated to changes in various immune cell number, function and activation phenotype. Obesity plays a central role in the development of T2DM. The inflammation originating from obese adipose tissue develops systemically and contributes to insulin resistance, beta cell dysfunction and hyperglycemia. Hyperglycemia can also contribute to chronic, low-grade inflammation resulting in compromised immune function. In this review, we explore how the trafficking of innate and adaptive immune cells under inflammatory condition is dysregulated in T2DM. We particularly highlight the obesity-related accumulation of leukocytes in the adipose tissue leading to insulin resistance and beta-cell dysfunction and resulting in hyperglycemia and consequent changes of adhesion and migratory behavior of leukocytes in different vascular beds. Thus, here we discuss how potential therapeutic targeting of leukocyte trafficking could be an efficient way to control inflammation as well as diabetes and its vascular complications.

U2 - 10.3389/fcell.2021.624184

DO - 10.3389/fcell.2021.624184

M3 - Review article

C2 - 33692997

VL - 9

JO - Frontiers in cell and developmental biology

JF - Frontiers in cell and developmental biology

SN - 2296-634X

M1 - 624184

ER -